South San Francisco-based Unity Biotechnology reported that the 12-week results from the company’s Phase II study of UBX0101 in moderate-to-severe painful osteoarthritis (OA) of the knee failed to show improvement over placebo.

Tanezumab, a non-opioid drug developed by Pfizer and Eli Lilly, met the main goals of a late-stage study in which over half of patients reported a significant reduction in hip or knee osteoarthritis pain.

So-called arthroscopic knee surgery is becoming a less common treatment for adults with torn cartilage or painful arthritis as a growing body of evidence shows little benefit from these operations, a U.S. study suggests.

Sanofi hired John Reed, the former top scientist at oncology market leader Roche, to head the drugmaker’s group research operations.

Anika Therapeutics Inc. announced results from the company’s CINGAL 16-02 clinical trial, an active-comparator Phase III study being conducted to support U.S. registration.

Flexion Therapeutics Inc.’s injectable drug to treat osteoarthritis-related knee pain was approved by the U.S. Food and Drug Administration, sending the drug developer’s shares soaring to a record high in regular trading.

The Korea Ministry of Food and Drug Safety granted marketing approval for Invossa-K Inj., the world’s first cell and gene therapy for degenerative arthritis.

Following mixed clinical trial results for its osteoarthritis of the knee injectable Hydros-TA, Carbylan Therapeutics said it is suspending clinical development of the therapy.

Cara Therapeutics Inc said its arthritis drug met the main goal of reducing pain in patients in the first mid-stage study. The oral drug, CR845, was being evaluated in patients with osteoarthritis in the knee or hip, the company said on Wednesday. Osteoarthritis, also known as degenerative arthritis, is a type of disease that results […]